Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGE-C2 TCR T cell therapy in melanoma and head and neck cancer
2024-516922-70-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Nov 2024
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MP71-MC2-TCR16-3D9 in melanoma and head and neck squamous cell carcinoma (HNSCC), sponsored by Erasmus MC. Planned start Nov 2024; status: authorised.
02
Drugs
MP71-MC2-TCR16-3D9
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-516922-70-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516922-70-00.